Innate Pharma S.A

Research Innate Pharma S.A (IDD) on Bullrun: market cap EUR 151.75M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIDD
• ExchangeF
• CountryFrance
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 151.75M
• Financial periodFY2025
• RevenueEUR 2.79M
• Revenue growth-77.9%
• Net income-EUR 49.18M
• Free cash flow-EUR 34.91M

Valuation Snapshot

latest market cap is EUR 151.75M.

About Innate Pharma S.A

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells.

Frequently asked questions

What is Innate Pharma S.A's market cap?

Innate Pharma S.A's market capitalization is EUR 151.75M.

What does Innate Pharma S.A do?

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.